Dr. Crater is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8801 Fast Park Drive
Suite 301
Raleigh, NC 27617Phone+1 919-371-8411
Summary
- No longer seeing patients.
Expert in clinical development in the medical device and pharmaceutical space.
Led programs leading to the approval of ADVAIR for COPD excaerbations, ANORO for COPD, NIOX VERO for asthma and PCD, YUPELRI for COPD.
Most recently led the development team at Inversago Pharma leading to it acquisition by NovoNordisk.
Education & Training
University of Tennessee Health Science Center College of MedicineClass of 1993
University of Florida College of Medicine JacksonvilleFellowship, Pulmonary Disease and Critical Care Medicine
Certifications & Licensure
NC State Medical License 2005 - 2025
TN State Medical License 1994 - 2005- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Pulmonary Disease
Publications & Presentations
PubMed
- 125 citationsOnce-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD: A Randomized, Controlled StudyBartolome R. Celli, Glenn Crater, Sally Kilbride, Rashmi Mehta, Maggie Tabberer
Chest. 2014-05-01 - 59 citationsA randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPDJames F. Donohue, Antonio Anzueto, Jean Brooks, Rashmi Mehta, Christopher Kalberg
Respiratory Medicine. 2012-07-01 - 182 citationsEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pul...Marc Decramer, Antonio Anzueto, Edward Kerwin, Thomas Kaelin, Nathalie Richard
The Lancet. Respiratory Medicine. 2014-06-01
Press Mentions
Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-Acting CB1 BlockerSeptember 7th, 2021- Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific SessionsJune 25th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
